Want to see JP:190A full AI Analyst Report?
190A Stock Chart & Stats
¥108.00
-¥9.00(-2.81%)
At close: 4:00 PM EST
¥108.00
-¥9.00(-2.81%)
Day’s Range― - ―
52-Week Range¥56.00 - ¥179.00
Previous CloseN/A
Volume2.20M
Average Volume (3M)542.06K
Market Cap
¥4.41B
Enterprise Value¥5.70B
Total Cash (Recent Filing)¥2.51B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Oct 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.05
Shares Outstanding77,358,400
10 Day Avg. Volume1,130,810
30 Day Avg. Volume542,056
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of reported debt reduces mandatory financing costs and refinancing exposure, giving Chordia greater flexibility while it funds oncology research. This can help preserve strategic options and limit balance-sheet stress, although it does not offset the company’s ongoing cash burn.
Proprietary Oncology Pipeline ModelChordia’s model is built around proprietary drug candidates and potential licensing or co-development partnerships, creating multiple routes to monetize successful research. If candidates advance, upfront payments, milestones, royalties or product sales could provide operating leverage beyond current R&D spending.
Prior Revenue And Profitability CapabilityThe 2023 results show that Chordia has previously generated substantial revenue and positive earnings, indicating its business can produce meaningful financial outcomes under favorable conditions. That historical capability provides a foundation for recovery if development activity again translates into monetizable products or partnerships.
Bears Say
Zero Recent Revenue And Large LossesThe return to zero revenue and substantial losses in 2024–2025 demonstrates that the company currently lacks a recurring commercial revenue base. Continued losses make financial performance dependent on future development success and increase the importance of securing product or partnership monetization.
Heavy Operating Cash BurnLarge operating and free-cash-flow outflows show that research spending is consuming cash without offsetting revenue. Persistent burn can reduce the resources available for clinical development and may eventually require additional funding, limiting flexibility even though the company reports no debt.
Shrinking Equity BaseMaterial equity erosion reflects sustained losses and weakens the capital base supporting future research. A strongly negative recent ROE indicates that shareholder capital is not currently generating returns, while continued depletion could constrain investment capacity and increase reliance on future financing.
Chordia Therapeutics Inc. News
190A FAQ
What was Chordia Therapeutics Inc.’s price range in the past 12 months?
Chordia Therapeutics Inc. lowest stock price was ¥56.00 and its highest was ¥179.00 in the past 12 months.
What is Chordia Therapeutics Inc.’s market cap?
Chordia Therapeutics Inc.’s market cap is ¥4.41B.
When is Chordia Therapeutics Inc.’s upcoming earnings report date?
Chordia Therapeutics Inc.’s upcoming earnings report date is Oct 15, 2026 which is in 2 days.
How were Chordia Therapeutics Inc.’s earnings last quarter?
Chordia Therapeutics Inc. released its earnings results on Jul 15, 2026. The company reported -¥14.45 earnings per share for the quarter.
Is Chordia Therapeutics Inc. overvalued?
According to Wall Street analysts Chordia Therapeutics Inc.’s price is currently Overvalued.
Does Chordia Therapeutics Inc. pay dividends?
Chordia Therapeutics Inc. does not currently pay dividends.
What is Chordia Therapeutics Inc.’s EPS estimate?
Chordia Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chordia Therapeutics Inc. have?
Chordia Therapeutics Inc. has 77,358,400 shares outstanding.
What happened to Chordia Therapeutics Inc.’s price movement after its last earnings report?
Chordia Therapeutics Inc. reported an EPS of -¥14.45 in its last earnings report. Following the earnings report the stock price went up 6.173%.
Which hedge fund is a major shareholder of Chordia Therapeutics Inc.?
Currently, no hedge funds are holding shares in JP:190A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chordia Therapeutics Inc.
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Tsubota Laboratory Incorporated
―
Shinnihonseiyaku Co., Ltd.
―
Heartseed, Inc.
―